

which is the last compound indicated in claim 5.


The compound of formula EX is a compound of formula III composed of the subgroups A-B-D-E-D'-C, wherein the following subgroups are elected:

Subgroup 1

A is species F, Tentagel, which comprises groups $-O-CH_2-CH_2-NH_2$ on its surface.


Subgroup 2

B is species A, benzyl, which is in the compound of the formula



Subgroup 3


The elected compound of formula I is of the formula



Subgroups 4 and 5


EITHER

D is species G, cyclic alkylamines, which is a compound of the formula



and

E is species A, low molecular weight compound, which is the amino acid β -alanin of the formula




and

D' is species A, a bond;


OR

D' is species I, amino acids, which is the amino acid β -alanin of the formula



and


E is species A, low molecular weight compound, which is a compound of the formula



and

D is species A, a bond.

Thus, the elected compound of formula III is composed of the following elements:



namely a compound of formula A-B-D-E-D'-C, wherein either D or D' is a bond and the other subgroups are as defined above.


A two-month extension is requested to respond to the Office Action of October 23, 2001.
Charge Deposit Account No. 19-0134 in the name of Novartis Corporation in the amount of **\$400** for payment of the extension fee.

Respectfully submitted,

Novartis Corporation
Patent and Trademark Dept.
564 Morris Avenue
Summit, NJ 07901-1027

encl: this page in duplicate

Date: 1/21/02


Gabriel Lopez
Attorney for Applicants
Reg. No. 28,440
(908) 522-6933